ChinaBio® maintains a team of researchers in Shanghai, performing primary and secondary research on a variety of subjects of interest to companies in the life science industry:

• Therapeutics, diagnostics and medical devices
• Novel technology development in China
• Clinical trial activity in China
• VC investment in life science companies
• M&A/IPO activity
• Partnering/collaboration deals

Examples of our findings from the 2008 data include:

Novel Technology Development (2000-2008)

• Over 1800 novel molecules have been patented in China since 2000;
• The #1 indication for novel molecules is oncology, followed by infectious disease and CVD;
• 68% of the novel molecules were developed by universitites and institutes; and
• Nearly 1/2 of all the novel molecules were developed in Shanghai and Beijing.

 Clinical Trial Activity (2004-2008)

• More than 100 novel molecules have been in clinical trials in China in the last five years;
• 76 novel molecules entered the clinic and 27 were launched;
• Over 150 novel molecules are in pre-clinical developent in China; and
• Nearly 1/2 of the candidates in trials are small molecules, followed by protein/peptide drugs and vaccines.

VC Investment (2008)

• VC investment declined (only) 20% in 2008 compared to 2007;
• Companies presenting at ChinaBio® Investor Forums raising funding in 2008 include HD Biosciences, GenePharma, PegBio, and ChiralQuest;
• Most active VCs in China include Morningside, Bay City Capital, Qiming, Mingly, Lilly, JAIC, and Fidelity; and
• Service companies received the largest portion of VC funding.

These and other data devloped by ChinaBio® gives us unique insights into China life science industry, and is used to build our proprietary databases and to support our consulting activities (see Consulting). 

Please contact us if you would like more information on the state of China life science.